

DEROGATION LETTER IN RESPECT OF INITIAL ENFORCEMENT ORDERS ISSUED PURSUANT TO SECTION 72(2) ENTERPRISE ACT 2002

Consent under section 72(3C) of the Enterprise Act 2002 (the 'Act') to certain actions for the purposes of the Initial Enforcement Order made by the Competition and Markets Authority ('CMA') on 27 August 2021 as varied on 30 September 2021

Completed acquisition by Dye & Durham Limited, through its subsidiary Dye & Durham (UK) Limited, of TM Group (UK) Limited (the 'Merger')

Dear [≫],

We refer to your submission of 3 May 2022 requesting that the CMA consents to derogations from the Initial Enforcement Order of 26 October 2021 (the "Initial Order"). Unless otherwise stated, the terms defined in the Initial Order have the same meaning in this letter.

Under the Initial Order, save for written consent by the CMA, Dye & Durham Limited and Dye & Durham (UK) Limited ("**D&D**") are required to hold separate the D&D business from the TM Group (UK) Limited ("**TMG**") business (together the "**Parties**") and refrain from taking any action which might prejudice a reference under section 22 of the Act or impede the taking of any remedial action following such a reference.

D&D UK business refers to the business of Dye & Durham (UK) Limited and its direct and indirect subsidiaries, carried on as at the commencement date of the Initial Order, but excluding Brady & Co (Law Searches) Limited (Registration number 265079) and its subsidiaries and the TMG business.

After due consideration of your request for derogations from the Initial Order, based on the information received from you and in the particular circumstances of this case, D&D may carry out the following actions, in respect of the specific paragraphs:

1. Paragraph 5(i) of the Initial Order – Changes made to key staff

The CMA understands that $[\aleph]$ has been appointed $[\aleph]$ with effect from 11 April 2022 and that his role to date has only involved D&D's Canadian business.

D&D is seeking the CMA's consent to a derogation from paragraph 5(i) of the IEO to permit the extension of [\gg] responsibilities as D&D's [\gg] to include the D&D UK business to ensure effective running of the business as a going concern.

On the basis of D&D's representations, the CMA consents to a derogation from paragraph 5(i) of the Initial Order to permit the extension of [\gg] responsibilities to the D&D UK business strictly on the basis that:



- (a) [≫] has the necessary capacity and experience to effectively fulfil the role as [≫]. As such, this appointment will not impact the viability or ongoing operation of the D&D or D&D UK business.
- (b) Save for the changes described above, no other organisational or key staff changes will be made to the D&D or D&D UK business as a result of the proposed appointment of [≫] as [≫].
- (c) This derogation will not lead to any integration of the TMG and D&D or D&D UK businesses and for the avoidance of doubt, will not result in any TMG staff reporting to [≫].
- (*d*) This derogation shall not prevent any remedial action that the CMA may need to take regarding the Merger.

The CMA also understands that it is necessary to promote [\gg] to the position of [\gg] to replace [\gg]. On the basis of D&D's representations, the CMA consents to a derogation from paragraph 5(i) of the Initial Order to permit [\gg] promotion to [\gg] strictly on the basis that:

- (a) [≫] has the necessary capacity and experience to effectively fulfil the role as [≫]. As such, this appointment will not impact the viability or ongoing operation of the D&D or D&D UK business.
- (b) Save for the changes described above, no other organisational or key staff changes will be made to the D&D or D&D UK business as a result of the proposed appointment of [≫] as [≫].
- (c) This derogation will not lead to any integration of the TMG and D&D or D&D UK businesses and for the avoidance of doubt, will not result in any TMG staff reporting to [≫].
- (d) This derogation shall not prevent any remedial action that the CMA may need to take regarding the Merger.

Yours sincerely.

Adam Cooper Director, Remedies, Business and Financial Analysis 5 May 2022